Abstract
To test the hypothesis that tricyclic antidepressant use increases invasive female breast cancer incidence, we carried out a case–control study within the population of female beneficiaries of the Saskatchewan Prescription Drug Plan aged ⩾35 years from 1981–1995 with no history of cancer since 1970. This agency has provided full or partial coverage for outpatient prescriptions to Saskatchewan residents since 1975. We accrued 5882 histologically proven cases and 23 517 controls, randomly selected from the source population and individually matched on age and sampling time. Heavy exposure to any tricyclic antidepressants was associated with an elevated rate ratio for breast cancer 11–15 years later (2.02, 95% confidence interval: 1.34–3.04). Post hoc analyses based on the results of genotoxicity studies carried out using Drosophila melanogaster suggested that the increased risk could be attributed to the use of the six genotoxic tricyclic antidepressants, and not to the use of the four nongenotoxic tricyclic antidepressants. However, our results may have been confounded by the effects of other determinants of breast cancer associated with tricyclic antidepressant use.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Budavari S, O'Neil MJ, Smith A, Heckelman PE (1989) The Merck Index. An Encyclopedia of Chemicals, Drugs, and Biologicals. Eleventh Edition Rahway, NJ: Merck
Coogan PF, Rosenberg L, Palmer JR, Strom BL, Stolley PD, Zauber AG, Shapiro S (2000) Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States). Cancer Causes Control 11: 839–845
Cotterchio M, Kreiger N, Darlington G, Steingart A (2000) Antidepressant medication use and breast cancer risk. Am J Epidemiol 151: 951–957
Dalton SO, Johansen C, Mellemkjær L, Sorensen HT, McLaughlin JK, Olsen J, Olsen JH (2000) Antidepressant medications and risk for cancer. Epidemiology 11: 171–176
Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S (1982) Nonestrogenic drugs and breast cancer. Am J Epidemiol 116: 329–332
Friedman GD, Ury HK (1980) Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 65: 723–733
Friedman GD, Ury HK (1983) Screening for possible drug carcinogenicity: second report of findings. J Natl Cancer Inst 71: 1165–1175
Gallo JJ, Armenian HK, Ford DE, Eaton WW, Khachaturian AS (2000) Major depression and cancer: the 13-year follow-up of the Baltimore Epidemiologic Catchment Area sample (United States). Cancer Causes Control 11: 751–758
Harlow BL, Cramer DW (1995) Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies (Massachusetts, United States). Cancer Causes Control 6: 130–134
Huberman M, Langholz B (1999) Application of the missing indicator method in matched case-control studies with incomplete data. Am J Epidemiol 150: 1340–1345
Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, Zauber AG, Shapiro S (1999) Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 150: 861–868
Land CE (1987) Temporal distributions of risk for radiation-induced cancers. J Chron Dis 40: Suppl 2 45–57
Linkins RW, Comstock GW (1990) Depressed mood and development of cancer. Am J Epidemiol 132: 962–972
MacMahon B, Trichopoulos D (1996) Epidemiology, Principles and Methods 2nd ed 250 Boston: Little, Brown
Marx J (1992) Do antidepressants promote tumors? Science 257: 22–23
Miettinen OS (1985) Theoretical Epidemiology. Principles of Occurrence Research in Medicine 226–227, Delmar: Albany
Miller LG (1993) Antidepressants and cancer: cause for concern? J Clin Psychopharm 13: 1–2
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (1997) Cancer Incidence in Five Continents Vol. VII: p 182 International Agency for Research on Cancer: Lyon
Penninx BWJH, Guralnick JM, Pahor M, Ferrucci L, Cerhan JR, Wallace RB, Havlik RJ (1998) Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 90: 1888–1893
Rawson NSB, D'Arcy C, Blackburn JL, Bowen RC, Wallace SM, Downey W, Senft D (1992) Epidemiologic research using linked computerized datafiles in Saskatchewan, Canada. Technical report series. In Report #2 Saskatoon: Psychiatric Pharmacoepidemiology Research Consortium
Selby JV, Friedman GD, Fireman BH (1989) Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 49: 5736–5747
Sharpe CR, Boivin JF (2000) The etiology of female breast cancer. Med Principles Pract 9: 1–24
Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA (2000) Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83: 112–120
Spiegel D (1996) Cancer and depression. Br J Psychiatr 168: Suppl 30 109–116
Steingart AB, Cotterchio M (1995) Do antidepressants cause, promote, or inhibit cancers? J Clin Epidemiol 48: 1407–1412
van Schaik N, Graf U (1991) Genotoxicity evaluation of five antidepressants in the wing somatic mutation and recombination test in Drosophila melanogaster. Mutation Res 260: 99–104
van Schaik N, Graf U (1993) Structure-activity relationships of tricyclic antidepressants and related compounds in the wing somatic mutation and recombination test of Drosophila melanogaster. Mutation Res 286: 155–163
Wallace RB, Sherman BM, Bean JA (1982) A case-control study of breast cancer and psychotropic drug use. Oncology 39: 279–283
Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J (2001) Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 54: 728–734
Weiss SR, McFarland BH, Burkhart GA, Ho PTC (1998) Cancer recurrences and second primary cancers after use of antihistamines or antidepressants. Clin Pharmacol Ther 63: 594–599
Acknowledgements
The study was funded by a grant (No. 007312) from the Canadian Breast Cancer Research Initiative. Dr CR Sharpe was supported by a postdoctoral fellowship from the Canadian Institutes of Health Research during part of the work and Dr JP Collet was supported by a grant from the Fonds de la Recherche en Santé du Québec. The study was based in part on data provided by the Saskatchewan Department of Health. The interpretation and conclusions contained in this report do not necessarily represent those of the Government of Saskatchewan or the Saskatchewan Department of Health. The study was also based on data provided by the Saskatchewan Cancer Agency, which bears no responsibility for the analysis of the data or the interpretation of the results.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sharpe, C., Collet, JP., Belzile, E. et al. The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 86, 92–97 (2002). https://doi.org/10.1038/sj.bjc.6600013
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600013
Keywords
This article is cited by
-
Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions
Oncogene (2023)
-
Cancer mortality in Common Mental Disorders: A 10-year retrospective cohort study
Social Psychiatry and Psychiatric Epidemiology (2023)
-
Molecularly imprinted polymers in toxicology: a literature survey for the last 5 years
Environmental Science and Pollution Research (2021)
-
A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency
BMC Medicine (2010)
-
Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line
Journal of Cancer Research and Clinical Oncology (2010)